Gelesis Holdings, Inc. (GLS)
$0.1586
0.00 (0.00%)
Rating:
Recommendation:
-
| Symbol | GLS |
|---|---|
| Price | $0.1586 |
| Beta | 0.994 |
| Volume Avg. | 0.57M |
| Market Cap | 11.631M |
| Shares () | - |
| 52 Week Range | 0.012-5.67 |
| 1y Target Est | - |
| DCF Unlevered | GLS DCF -> | |
|---|---|---|
| DCF Levered | GLS LDCF -> | |
| ROE | -1744909.49% | Strong Sell |
| ROA | -42276138.03% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | -462.12% | Strong Sell |
| P/E | -0.12 | Neutral |
| P/B | -0.44 | Neutral |
Latest GLS news
About
Download (Excel)Gelesis Holdings Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. The company also provides PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, it offers a product for obesity and overweight and a pipeline with potential therapies for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, type 2 diabetes, and GS500 for Functional Constipation. Gelesis Holdings Inc. was incorporated in 2006 and is headquartered in Boston, Massachusetts.